The End of Unlinked Chart Review: What It Means for 2027 | Inferscience
CMS CY2027 Rate Notice

The end of unlinked chart review: what it means for 2027

CMS is excluding unlinked chart review diagnoses from Medicare Advantage risk adjustment starting with 2026 dates of service. Every HCC now has to trace to a documented encounter. Here is what changes, and how to stay ahead of it.

Let's talk
CY2027
exclusion takes effect
$7B+
projected MA payment reduction
2026
dates of service already affected

Source: CMS CY2027 Rate Announcement, finalized April 2026.

The short answer

What is unlinked chart review, and what changed?

An unlinked chart review is a chart audit that produces a diagnosis code with no encounter record showing a service was actually provided. CMS is now excluding those diagnoses from Medicare Advantage risk scores.

Plans have long used unlinked chart reviews to raise beneficiary risk scores, and payments, without a documented visit behind the code. Starting with 2026 dates of service, CMS is finalizing the exclusion of unlinked chart review records (and audio-only encounters) from risk adjustment. The change is projected to reduce MA payments by roughly 1.53%, or more than $7 billion, in 2027. There is a limited exception for beneficiaries who switch from one MA organization to another.

What it means for you

Every HCC now has to trace to a documented encounter

Retrospective-only strategies lose ground

Codes recovered by chart audit without a linked encounter no longer count. Back-end review alone is no longer enough.

Point-of-care capture becomes essential

The reliable way to keep every HCC is to capture and document it during the visit, tied to a real encounter.

Documentation has to be defensible

With tighter scrutiny and expanding RADV audits, every diagnosis needs MEAT-supported evidence behind it.

How to stay ahead

Capture the risk picture at the point of care

Inferscience is built for the world after unlinked chart review. Its HCC Assistant surfaces missed and suspected HCCs during the visit, inside the EHR, at 98% coding accuracy, so diagnoses are documented against a real encounter rather than recovered afterward.

Its HCC Validator then confirms every diagnosis meets MEAT criteria before submission and links each code to its source documentation, building a defensible, RADV-ready trail. Together they replace the risk-adjustment value that unlinked chart review used to provide, in a way that holds up under CMS scrutiny. A 700-provider clinically integrated network has coded with Inferscience inside athenaOne since 2020.

Read the case study →

Frequently asked questions

What is an unlinked chart review?

An unlinked chart review is a chart audit that generates a diagnosis code without any encounter record showing a service was actually provided. CMS is excluding these diagnoses from Medicare Advantage risk adjustment.

When does the unlinked chart review exclusion take effect?

CMS finalized the exclusion in its CY2027 Rate Announcement (April 2026). It applies starting with 2026 dates of service, affecting 2027 payment.

How much will it affect Medicare Advantage payments?

CMS projects the change will reduce MA payments by roughly 1.53%, or more than $7 billion, in 2027 compared to 2026.

What should provider organizations do about it?

Shift from recovering codes by retrospective chart audit to capturing and documenting diagnoses at the point of care, tied to a real encounter and supported by MEAT evidence. Real-time, EHR-native coding is the most reliable way to do this.

How does Inferscience help?

HCC Assistant captures HCCs during the visit inside the EHR, and HCC Validator confirms MEAT support and links each code to its documentation, so your risk scores stay accurate and defensible without relying on unlinked chart reviews.

Stay ahead of the 2027 change

See how Inferscience keeps your risk scores defensible after unlinked chart review.

Let's talk